Through the Looking Glass:
Seeing a Better Future in Crohn’s Disease
Evolving Treatment Targets & Monitoring Strategies in Crohn's Disease: Clinical Convo
This activity is jointly provided by Partners for Advancing Clinical Education (PACE) and Bonum CE
This activity is supported by an educational grant from Lilly.
Program Overview
While historically the goals of Crohn’s disease treatment were limited to symptomatic clinical remission, the availability of disease-modifying therapies have now extended treatment goals to include that of sustained deep remission. Coupled with these paradigm shifts were the introduction of newer management strategies, including the early introduction of highly effective therapy, a tight and frequent control of mucosal inflammation, and adjustments in treatment based on endpoints and assessments. This MondayNightIBD Clinical Conversation, hosted on Twitter/X focuses on the translation of data supporting a treat-to-target approach into clinical management of patients with Crohn’s disease.
Faculty
Aline Charabaty, MD, FACG, AGAF (program chair)
Associate Professor of Medicine
Johns Hopkins School of Medicine
Medical Director of the Division of Gastroenterology and Hepatology
Clinical Director of the IBD Center at Johns Hopkins
Sibley Memorial Hospital
Washington, D.C.
Jami Kinnucan, MD, FACG, AGAF, FCCF (guest faculty)
Senior Associate Consultant, Division of Gastroenterology and Hepatology
GI Practice Chair for the Division of Gastroentrology and Hepatology
Director of Intestinal Ultrasound Program
Mayo Clinic
Jacksonville, FL
Target Audience
The target audience for this program is IBD specialists, gastroenterologists, gastroenterology fellows and trainees, nurse practitioners and physician’s assistants who care for patients with Crohn’s disease. Additionally, nurses, specialty pharmacists and other healthcare practitioners involved or interested in the care of patients with Crohn’s disease.
Learning Objectives
After completing this activity series, learners should be better able to utilize best practices and data supporting treat-to-target approach for optimized care of patients with Crohn’s disease.
Disclosure of Relevant Financial Relationships
PACE requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated according to PACE policies. Others involved in the planning of this activity have no relevant financial relationships.
-
Aline Charabaty, MD, FACG, AGAF
Consultant & Advisor: AbbVie, Janssen, Eli Lilly, Pfizer, Takeda
Jami Kinnucan, MD, FACG, AGAF, FCCF
Consultant & Advisor: AbbVie, Fresinius Kabi, Janssen, Lilly, Pfizer, Takeda, UCB
Joint Accreditation Statement
Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (PACE) and Bonum CE. PACE is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician Continuing Medical Education
PACE designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Instructions to Receive Credit & Fee Information
In order to receive credit for this activity, the participant must read the front matter, achieve a passing score of 100% on the post-test, complete the evaluation and application for credit form.
There is no fee to participate in this activity.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimers
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
System Requirements
All Bonum CE digital activities require the following hardware/software to view and participate:
Internet connection (via PC or Mac desktop or laptop computer, tablet, mobile device, etc.)
PowerPoint and/or a PDF viewer may be required on some activities
We recommend a minimum of:
128MB RAM
Processor speed of 500MHz or higher
800x600 color monitor
Video or graphics card
Sound card and speakers
To actively participate in Bonum’s social media (SoMe)-based CME programs, learners will need to have an established account in good standing on that hosting SoMe site. Learners will need to be logged-in to the SoMe hosting platform.
For additional information about the accreditation of this activity, please visit https://www.partnersed.com
Release date: October 21, 2024
Expiration date: October 21, 2025
Estimated time to complete activity: 60 minutes